[en] Infective endocarditis is a challenging disease with a high mortality and morbidity rate. Antibiotic prophylaxis is currently recommended in high-risk infective endocarditis patients. However, the use of antibiotics faces the challenge of a low efficacy and contributes further to the emerging infection rate by antibiotic-resistant strains, emphasizing the need for new therapeutic strategies. Platelets are essential in the initial phase of infective endocarditis, acting as first-line immune responders. During the first phase of disease, bacteria can interact with platelets and counteract platelet antimicrobial activities. Mechanistic in vitro and animal studies on the effect of aspirin on bacteria-platelet interactions and the prevention of vegetation development showed promising results. However, data from clinical studies on the outcome of infective endocarditis patients who were receiving medically indicated aspirin therapy remain controversial. Therefore, the benefit of antiplatelet agents in infective endocarditis prevention has been questioned. Besides aspirin, it has been discovered that the platelet P2Y12 receptor antagonist ticagrelor has antibacterial properties in addition to its potent antiplatelet activity. Furthermore, a recent study in mice and a case report remarkably indicated the ability of this drug to eradicate Staphylococcus aureus bacteremia. This review will focus on current knowledge on antibacterial activity of ticagrelor, compared to aspirin, pointing out main unanswered questions. The goal is to provide food for thought as to whether a prior ticagrelor therapy might be beneficial for the prevention of infective endocarditis.
Research center :
Laboratory of Cardiology, Department of Cardiology, GIGA Institute, University of Liège Hospital, Liège, Belgium Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola, and Anthea Hospital, Bari, Italy
Anavekar N. S. Tleyjeh I. M. Anavekar N. S. Mirzoyev Z. Steckelberg J. M. Haddad C. et al. (2007). Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin. Infect. Dis. 44 1180–1186. 10.1086/513197 17407036
Bayer A. S. Ramos M. D. Menzies B. E. Yeaman M. R. Shen A. J. Cheung A. L. (1997). Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect. Immun. 65 4652–4660. 10.1128/iai.65.11.4652-4660.1997 9353046
Bhakdi S. Muhly M. Mannhardt U. Hugo F. Klapettek K. Mueller-Eckhardt C. et al. (1988). Staphylococcal α toxin promotes blood coagulation via attack on human platelets. J. Exp. Med. 168 527–542. 10.1084/jem.168.2.527 3411289
Cahill T. J. Prendergast B. D. (2016). Infective endocarditis. Lancet 387 882–893. 10.1016/S0140-6736(15)00067-7
Chan K. L. Dumesnil J. G. Cujec B. Sanfilippo A. J. Jue J. Turek M. A. et al. (2003). A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J. Am. Coll. Cardiol. 42 775–780. 10.1016/S0735-1097(03)00829-5
Chan K. L. Tam J. Dumesnil J. G. Cujec B. Sanfilippo A. J. Jue J. et al. (2008). Effect of long-term aspirin use on embolic events in infective endocarditis. Clin. Infect. Dis. 46 37–41. 10.1086/524021 18171211
Claes J. Ditkowski B. Liesenborghs L. Veloso T. R. Entenza J. M. Moreillon P. et al. (2018). Assessment of the dual role of clumping factor A in S. Aureus adhesion to endothelium in absence and presence of plasma. Thromb. Haemost. 118 1230–1241. 10.1055/s-0038-1660435 29909601
Claes J. Liesenborghs L. Peetermans M. Veloso T. R. Missiakas D. Schneewind O. et al. (2017). Clumping factor A, von Willebrand factor-binding protein and von Willebrand factor anchor Staphylococcus aureus to the vessel wall. J. Thromb. Haemost. 15 1009–1019. 10.1111/jth.13653 28182324
Cox D. Kerrigan S. W. Watson S. P. (2011). Platelets and the innate immune system: mechanisms of bacterial-induced platelet activation. J. Thromb. Haemost. 9 1097–1107. 10.1111/j.1538-7836.2011.04264.x 21435167
Eisen D. P. Corey G. R. McBryde E. S. Fowler V. G. Miro J. M. Cabell C. H. et al. (2009). Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J. Infect. 58 332–338. 10.1016/j.jinf.2009.03.006 19342103
Gaertner F. Ahmad Z. Rosenberger G. Fan S. Nicolai L. Busch B. et al. (2017). Migrating platelets are mechano-scavengers that collect and bundle bacteria. Cell 171 1368.e–1382.e. 10.1016/j.cell.2017.11.001 29195076
Gordon C. P. Williams P. Chan W. C. (2013). Attenuating Staphylococcus aureus virulence gene regulation: a medicinal chemistry perspective. J. Med. Chem. 56 1389–1404. 10.1021/jm3014635 23294220
Habib A. Irfan M. Baddour L. M. Le K. Y. Anavekar N. S. Lohse C. M. et al. (2013). Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Europace 15 227–235. 10.1093/europace/eus292 22956593
Habib G. Lancellotti P. Erba P. A. Sadeghpour A. Meshaal M. Sambola A. et al. (2019). The ESC-EORP EURO-ENDO (European Infective Endocarditis) registry. Eur. Heart J. Qual. Care Clin. Outcomes 5 202–207. 10.1093/ehjqcco/qcz018 30957862
Hamzeh-Cognasse H. Damien P. Chabert A. Pozzetto B. Cognasse F. Garraud O. (2015). Platelets and infections-Complex interactions with bacteria. Front. Immunol. 6:82. 10.3389/fimmu.2015.00082 25767472
Hannachi N. Ogé-Ganaye E. Baudoin J. P. Fontanini A. Bernot D. Habib G. et al. (2020). Antiplatelet agents have a distinct efficacy on platelet aggregation induced by infectious bacteria. Front. Pharmacol. 11:863. 10.3389/fphar.2020.00863 32581813
Heying R. Vanassche T. Moreillon P. (2019). Are antiplatelet agents beneficial in prevention of infective endocarditis? JAMA Cardiol. 4:1177. 10.1001/jamacardio.2019.3130 31483440
Holinstat M. (2017). Normal platelet function. Cancer Metastasis Rev. 36 195–198. 10.1007/s10555-017-9677-x 28667366
Holland T. L. Baddour L. M. Bayer A. S. Hoen B. Miro J. M. Fowler V. G. (2016). Infective endocarditis. Nat. Rev. Dis. Prim. 2:16059. 10.1038/nrdp.2016.59 27582414
Kerrigan S. W. Clarke N. Loughman A. Meade G. Foster T. J. Cox D. (2008). Molecular basis for Staphylococcus aureus-mediated platelet aggregate formation under arterial shear in vitro. Arterioscler. Thromb. Vasc. Biol. 28 335–340. 10.1161/ATVBAHA.107.152058 18063809
Kupferwasser L. I. Skurray R. A. Brown M. H. Firth N. Yeaman M. R. Bayer A. S. (1999a). Plasmid-mediated resistance to thrombin-induced platelet microbicidal protein in Staphylococci: role of the qacA locus. Antimicrob. Agents Chemother. 43 2395–2399. 10.1128/aac.43.10.2395 10508013
Kupferwasser L. I. Yeaman M. R. Nast C. C. Kupferwasser D. Xiong Y.-Q. Palma M. et al. (2003). Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J. Clin. Invest. 112 222–233. 10.1172/jci16876 12865410
Kupferwasser L. I. Yeaman M. R. Shapiro S. M. Nast C. C. Sullam P. M. Filler S. G. et al. (1999b). Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 99 2791–2797. 10.1161/01.CIR.99.21.2791
Lancellotti P. Musumeci L. Jacques N. Servais L. Goffin E. Pirotte B. et al. (2019a). Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant gram-positive bacteria. JAMA Cardiol. 4 596–599. 10.1001/jamacardio.2019.1189 31066863
Lancellotti P. Musumeci L. Oury C. (2019b). Are antiplatelet agents beneficial in prevention of infective endocarditis?-Reply. JAMA Cardiol. 4 1177–1178.
Liesenborghs L. Meyers S. Lox M. Criel M. Claes J. Peetermans M. et al. (2019). Staphylococcus aureus endocarditis: distinct mechanisms of bacterial adhesion to damaged and inflamed heart valves. Eur. Heart J. 40 3248–3259. 10.1093/eurheartj/ehz175 30945735
Liesenborghs L. Meyers S. Vanassche T. Verhamme P. (2020). Coagulation: at the heart of infective endocarditis. J. Thromb. Haemost. 18 995–1008. 10.1111/jth.14736 31925863
Liesenborghs L. Verhamme P. Vanassche T. (2018). Staphylococcus aureus, master manipulator of the human hemostatic system. J. Thromb. Haemost. 16 441–454. 10.1111/jth.13928 29251820
Lupu L. Shepshelovich D. Banai S. Hershkoviz R. Isakov O. (2020). Effect of ticagrelor on reducing the risk of gram-positive infections in patients with acute coronary syndrome. Am. J. Cardiol. 130 56–63. 10.1016/j.amjcard.2020.06.016 32680674
Moreillon P. Que Y. A. (2004). Infective endocarditis. Lancet 363 139–149. 10.1016/S0140-6736(03)15266-X
Nicolau D. P. Marangos M. N. Nightingale C. H. Quintiliani R. (1995). Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 39 1748–1751. 10.1128/AAC.39.8.1748 7486913
Nicolau D. P. Tessier P. R. Nightingale C. H. (1999). Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int. J. Antimicrob. Agents 11 159–161. 10.1016/S0924-8579(98)00092-2
Pawar P. Shin P. K. Mousa S. A. Ross J. M. Konstantopoulos K. (2004). Fluid shear regulates the kinetics and receptor specificity of Staphylococcus aureus binding to activated platelets. J. Immunol. 173 1258–1265. 10.4049/jimmunol.173.2.1258 15240718
Pepin J. Tremblay V. Bechard D. Rodier F. Walker C. Dufresne D. et al. (2009). Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin. Microbiol. Infect. 15 193–199. 10.1111/j.1469-0691.2008.02665.x 19196260
Powers M. E. Becker R. E. N. Sailer A. Turner J. R. Bubeck Wardenburg J. (2015). Synergistic action of Staphylococcus aureus α-toxin on platelets and myeloid lineage cells contributes to lethal sepsis. Cell Host Microbe 17 775–787. 10.1016/j.chom.2015.05.011 26067604
Powers M. E. Kim H. K. Wang Y. Wardenburg J. B. (2012). ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J. Infect. Dis. 206 352–356. 10.1093/infdis/jis192 22474035
Que Y. A. Moreillon P. (2011). Infective endocarditis. Nat. Rev. Cardiol. 8 322–336. 10.1038/nrcardio.2011.43 21487430
Sexton T. R. Zhang G. Macaulay T. E. Callahan L. A. Charnigo R. Vsevolozhskaya O. A. et al. (2018). Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl. Sci. 3 435–449. 10.1016/j.jacbts.2018.05.005 30175268
Snygg-Martin U. Rasmussen R. V. Hassager C. Bruun N. E. Andersson R. Olaison L. (2011). The relationship between cerebrovascular complications and previously established use of antiplatelet therapy in left-sided infective endocarditis. Scand. J. Infect. Dis. 43 899–904. 10.3109/00365548.2011.603742 21916774
Sørensen A. L. Rumjantseva V. Nayeb-Hashemi S. Clausen H. Hartwig J. H. Wandall H. H. et al. (2009). Role of sialic acid for platelet life span: exposure of β-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 114 1645–1654. 10.1182/blood-2009-01-199414 19520807
Sun J. Uchiyama S. Olson J. Morodomi Y. Cornax I. Ando N. et al. (2021). Repurposed drugs block toxin-driven platelet clearance by the hepatic Ashwell-Morell receptor to clear Staphylococcus aureus bacteremia. Sci. Transl. Med. 13:eabd6737. 10.1126/scitranslmed.abd6737 33762439
Surewaard B. G. J. Thanabalasuriar A. Zeng Z. Tkaczyk C. Cohen T. S. Bardoel B. W. et al. (2018). α-Toxin Induces Platelet Aggregation and Liver Injury during Staphylococcus aureus Sepsis. Cell Host Microbe 24 271.e–284.e. 10.1016/j.chom.2018.06.017 30033122
Tiwari N. R. Chaudhari K. S. Sharma R. Haas K. P. Sharma V. R. (2020). Antiplatelet agents in sepsis-putting it all together: a call to action. Indian J. Crit. Care Med. 24 483–484. 10.5005/jp-journals-10071-23450 32863646
Tong S. Y. C. Davis J. S. Eichenberger E. Holland T. L. Fowler V. G. (2015). Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin. Microbiol. Rev. 28 603–661. 10.1128/CMR.00134-14 26016486
Trauer J. Muhi S. McBryde E. S. Al Harbi S. A. Arabi Y. M. Boyle A. J. et al. (2017). Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: an individual patient data meta-analysis using propensity matching. Crit. Care Med. 45 1871–1879. 10.1097/CCM.0000000000002654 28799949
Ulloa E. R. Uchiyama S. Gillespie R. Nizet V. Sakoulas G. (2021). Ticagrelor increases platelet-mediated Staphylococcus aureus killing resulting in clearance of bacteremia. J. Infect. Dis. 146:jiab146. 10.1093/infdis/jiab146 33966075
Veloso T. R. Oechslin F. Que Y. A. Moreillon P. Entenza J. M. Mancini S. (2015a). Aspirin plus ticlopidine prevented experimental endocarditis due to Enterococcus faecalis and Streptococcus gallolyticus. Pathog. Dis. 73:ftv060.
Veloso T. R. Que Y.-A. Chaouch A. Giddey M. Vouillamoz J. Rousson V. et al. (2015b). Prophylaxis of experimental endocarditis with antiplatelet and antithrombin agents: a role for long-term prevention of infective endocarditis in humans? J. Infect. Dis. 211 72–79. 10.1093/infdis/jiu426 25086177
Wallentin L. Becker R. C. Budaj A. Cannon C. P. Emanuelsson H. Held C. et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361 1045–1057. 10.1056/nejmoa0904327 19717846
Wann E. R. Gurusiddappa S. Hook M. (2000). The fibronectin-binding MSCRAMM FnbpA of Staphylococcus aureus is a bifunctional protein that also binds to fibrinogen. J. Biol. Chem. 275 13863–13871. 10.1074/jbc.275.18.13863 10788510
Werdan K. Dietz S. Löffler B. Niemann S. Bushnaq H. Silber R. E. et al. (2014). Mechanisms of infective endocarditis: pathogen-host interaction and risk states. Nat. Rev. Cardiol. 11 35–50. 10.1038/nrcardio.2013.174 24247105
Wilson W. Taubert K. A. Gewitz M. Lockhart P. B. Baddour L. M. Levison M. et al. (2007). Prevention of infective endocarditis: guidelines from the American Heart Association. Circulation 116 1736–1754. 10.1161/CIRCULATIONAHA.106.183095 17446442
Wong C. H. Y. Jenne C. N. Petri B. Chrobok N. L. Kubes P. (2013). Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat. Immunol. 14 785–792. 10.1038/ni.2631 23770641
Yeaman M. R. (2010). Platelets in defense against bacterial pathogens. Cell. Mol. Life Sci. 67 525–544. 10.1007/s00018-009-0210-4 20013024
